Curated News
By: NewsRamp Editorial Staff
June 23, 2026
Alcanza Clinical Research Acquires CNS Healthcare, Expanding Neuroscience Capabilities
TLDR
- Alcanza Clinical Research gains a competitive edge by acquiring CNS Healthcare's established network and expertise in neuroscience and behavioral health trials.
- CNS Healthcare, founded in 1996, has completed thousands of clinical trials across neuroscience and behavioral health, expanding Alcanza's multispecialty capabilities.
- The acquisition advances Alcanza's mission 'Clinical Research for All' by broadening access to diverse communities and inclusive patient engagement.
- CNS Healthcare operates a mobile clinical trial vehicle, enabling research to reach patients beyond fixed locations.
Impact - Why it Matters
This acquisition matters because it directly expands access to clinical trials for under-represented communities, particularly in neuroscience and behavioral health. By combining Alcanza's inclusive mission with CNS Healthcare's 30-year expertise, more patients—especially those from diverse backgrounds—will have opportunities to participate in studies for life-changing treatments. This move accelerates medical progress while ensuring that clinical research reflects the real-world population, ultimately leading to more effective and equitable healthcare solutions.
Summary
LAKE MARY, FL – Alcanza Clinical Research has acquired CNS Healthcare, a respected independent clinical research network with a 30-year legacy in neuroscience and behavioral health. Founded in 1996, CNS Healthcare has completed thousands of clinical trials across key therapeutic areas, operating from five locations in Memphis, Jacksonville, Orlando, and a mobile clinical trial vehicle. Known for high-quality data and patient-centric care, CNS Healthcare has been a preferred partner for global sponsors. The acquisition bolsters Alcanza's mission of 'Clinical Research for All™' by expanding its multispecialty capabilities and site network to over 30 locations across the US and Puerto Rico.
Under CEO Dan Kearney, CNS Healthcare built a strong reputation with experienced Principal Investigators and consistent trial performance. Kearney expressed excitement about joining Alcanza, highlighting the shared commitment to inclusiveness. Alcanza CEO Carlos Orantes welcomed the team, emphasizing the focus on high-performing research sites. The integration enhances Alcanza's capacity to deliver life-changing treatments to diverse communities, particularly under-represented populations.
This strategic move strengthens Alcanza's network of dedicated research units and integrated specialty clinics, supporting studies across all trial phases and major therapeutic areas. The combined organization is poised to accelerate medical breakthroughs by leveraging CNS Healthcare's legacy and Alcanza's inclusive approach, ultimately bringing clinical trial opportunities to more patients. The anchor text Alcanza Clinical Research is central to this news, highlighting the company's growth and dedication to inclusive clinical research.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, Alcanza Clinical Research Acquires CNS Healthcare, Expanding Neuroscience Capabilities
